tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany AnnouncementsRhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
7d ago
Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating
Premium
Ratings
Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating
8d ago
Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Strong Sales and Promising Growth Prospects
Premium
Ratings
Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Strong Sales and Promising Growth Prospects
8d ago
Rhythm Pharmaceuticals reports Q2 EPS (75c), consensus (67c)
PremiumThe FlyRhythm Pharmaceuticals reports Q2 EPS (75c), consensus (67c)
9d ago
Rhythm Pharmaceuticals announces anticipated upcoming milestones
Premium
The Fly
Rhythm Pharmaceuticals announces anticipated upcoming milestones
9d ago
Rhythm Pharmaceuticals enrolls first patient in Part C of Phase 1 RM-718 trial
Premium
The Fly
Rhythm Pharmaceuticals enrolls first patient in Part C of Phase 1 RM-718 trial
9d ago
Rhythm Pharmaceuticals’ Promising Phase 2 Study on LB54640 for Hypothalamic Obesity
PremiumCompany AnnouncementsRhythm Pharmaceuticals’ Promising Phase 2 Study on LB54640 for Hypothalamic Obesity
23d ago
Rhythm Pharmaceuticals price target raised to $105 from $92 at Canaccord
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $105 from $92 at Canaccord
27d ago
Promising Potential of Rhythm Pharmaceuticals’ Treatments for Hypothalamic Obesity Drives Buy Rating
Premium
Ratings
Promising Potential of Rhythm Pharmaceuticals’ Treatments for Hypothalamic Obesity Drives Buy Rating
30d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100